Skip to content
Screener

Alumis Inc. ALMS EBITDA

EBITDA at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$4.68B+68.1%
Amgen logo
AmgenAMGN
$4.63B+15.7%
Immunome logo
ImmunomeIMNM
-$58.73M-33.4%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-$36.39M-45.2%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$31.5M-64.2%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$60.1M+61.7%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.54B+686%
Enterprise value$3.52B+940%
P/S421.8×—

Profitability

See full
Operating margin-5,364%—
Net margin-2,825.7%—
FCF margin-4,487.4%—

Returns & leverage

See full
Return on equity-64.6%—
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

−$98.4Mebit+
$871.0KDepreciation Depletion & Amortization
=-$97.54M

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026. Open the filing →

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010

FAQ

What is Alumis Inc.'s EBITDA?
Alumis Inc. (ALMS) reported EBITDA of -$97.54M in Q1 2026.
How has Alumis Inc.'s EBITDA changed year-over-year?
Alumis Inc.'s EBITDA increased by 3.1% year-over-year, from -$100.69M to -$97.54M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.

Ask your AI about Alumis Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude